Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

101. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. (PubMed)

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. To determine the effectiveness of increasing the dietary content of soluble fibre (psyllium) or insoluble fibre (bran) in patients with irritable bowel syndrome.Randomised controlled trial.General practice.275 patients aged 18-65 years with irritable bowel syndrome.12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93).The primary end point (...) was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritable bowel syndrome symptom severity score, severity of abdominal pain, and irritable bowel syndrome quality of life scale.The proportion of responders was significantly greater in the psyllium group than in the placebo group during the first month (57% v 35%; relative risk 1.60, 95

Full Text available with Trip Pro

2009 BMJ

102. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Rahimi R, Nikfar S, Rezaie A, Abdollahi M CRD summary This review concluded that low-dose tricyclic antidepressants (TCAs) exhibited clinically and statistically significant control of irritable bowel syndrome (IBS) symptoms. Caution is warranted (...) in the application of the results as reported TCA effects may have been overestimated given the small number of studies and patients reviewed. Authors' objectives To assess the efficacy of tricyclic antidepressants (TCAs) in patients with irritable bowel syndrome (IBS). Searching PubMed, Scopus, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) were searched (from 1966 to September 2008) for English-language papers. Search terms were reported. Reference lists of retrieved articles were

2009 DARE.

103. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS CRD summary This review evaluated efficacy, safety and tolerability of probiotics in irritable bowel syndrome and concluded that Bifidobacterium infantis 35624 showed efficacy (...) in improving symptoms; data for other probiotics were inadequate. The conclusion that evidence on probiotics was of poor quality appeared appropriate, although conclusions about the efficacy of B. infantis may be less reliable. Authors' objectives To evaluate efficacy, safety and tolerability of probiotics in treatment of irritable bowel syndrome (IBS). Searching MEDLINE, PubMed, EMBASE and The Cochrane Library were searched from inception to June 2008 to identify relevant articles published in English

2009 DARE.

104. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P CRD summary The authors concluded that alosetron, cilansetron and tegaserod (drugs acting (...) on 5-hydroxytryptamine receptors) were all effective in irritable bowel syndrome; serious adverse events were rare in trials included in this review. This was generally a well-conducted review and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the effectiveness of 5-hydroxytryptamine 3 (5-HT 3 ) antagonists and 5-hydroxytryptamine 4 (5-HT 4 ) agonists in adults with irritable bowel syndrome (IBS). Searching MEDLINE (from 1950), EMBASE (from 1980

2009 DARE.

105. Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome

Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndromeCommentary | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) improve symptoms of irritable bowel syndrome Commentary Statistics from Altmetric.com QUESTION In patients with irritable bowel syndrome (IBS), do antidepressant medications or psychological therapies improve symptoms? REVIEW SCOPE Included studies compared antidepressants with placebo or psychological therapies with no treatment or usual care in adults (⩾16 y of age) with IBS diagnosed by established criteria or by a clinician’s opinion. Outcomes were persistent IBS symptoms and adverse events

2009 Evidence-Based Medicine (Requires free registration)

106. Psychological treatments may be effective for managing irritable bowel syndrome

Psychological treatments may be effective for managing irritable bowel syndrome PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Psychological treatments may be effective for managing irritable bowel syndrome Clinical question How effective are psychological interventions for the treatment of irritable bowel syndrome (IBS)? Bottom line Psychological interventions (cognitive behavioural therapy (...) of irritable bowel syndrome. Cochrane Reviews 2009, Issue 1. Article No: CD006442. DOI: 10.1002/14651858.CD006442.pub2. This review contains 25 studies involving 1858 participants. PEARLS 156, April 2009, written by Brian R McAvoy [References] 1. Drossman DA et al. Gastroenterology 1997;112:2120-2137 are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement

2009 Cochrane PEARLS

107. Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome

Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Article Text Diagnosis Review: clinical findings had moderate sensitivity

2009 Evidence-Based Medicine (Requires free registration)

108. Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome

Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Article Text Therapeutics Review: fibre, antispasmodics, and peppermint oil are all effective

2009 Evidence-Based Medicine (Requires free registration)

109. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P CRD summary The authors concluded that antidepressants were effective (...) in the treatment of irritable bowel syndrome, and psychological therapies may be of comparable efficacy to antidepressants, but there was lack of high quality evidence. Given the risk of publication bias, the presence of statistical heterogeneity, and the low quality of available trials, the reliability of the authors' conclusions regarding antidepressants is unclear. Authors' objectives To assess the efficacy of anti-depressant medication and psychological therapies in alleviating symptoms of irritable bowel

2009 DARE.

110. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

111. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

112. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

113. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. (PubMed)

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.Systematic review and meta-analysis of randomised controlled trials.Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil (...) with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting

Full Text available with Trip Pro

2008 BMJ

114. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome (PubMed)

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS).To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were (...) given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics

Full Text available with Trip Pro

2008 EvidenceUpdates

115. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? (PubMed)

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Many individuals experience lower gastrointestinal tract symptoms, most commonly attributable to functional conditions. These individuals are frequently diagnosed with irritable bowel syndrome (IBS) based on their symptoms; however, some may require additional testing or referral to specialists before this diagnosis is made.To systematically

2008 JAMA

116. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome (PubMed)

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function.To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial.Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure

Full Text available with Trip Pro

2008 EvidenceUpdates

117. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents (PubMed)

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents.Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed

2008 EvidenceUpdates

118. Effectiveness of probiotics in the treatment of irritable bowel syndrome (PubMed)

Effectiveness of probiotics in the treatment of irritable bowel syndrome Recently, the use of tegaserod and alosetron -- drugs approved for the treatment of irritable bowel syndrome (IBS) -- has been restricted because of adverse events. This has resulted in a need for additional modalities for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit

2008 EvidenceUpdates

119. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review (PubMed)

Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review Irritable bowel syndrome (IBS) is a common disorder that occurs in adults. The natural history of symptoms and risk factors that contribute to IBS may begin in childhood. The aim of this systematic review was to determine what early life factors contribute to the development of IBS in adolescents and adults.A computer-assisted search of the PubMed database from 1966 to 2007 was performed

Full Text available with Trip Pro

2008 EvidenceUpdates

120. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (PubMed)

Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Although most children are managed by reassurance and simple measures, a large range of psychosocial interventions

2008 Cochrane